{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-008937","form_type":"8-K","ticker":"BNBX","cik":"0000744452","company_name":"BNB PLUS CORP.","filed_at":"2024-02-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.853202+00:00","generated_at":"2026-06-06T12:13:48.668951+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Applied DNA Sciences raises ~$3.44M in registered direct offering at $0.609/share","bullets":["Gross proceeds expected $3.44M from 5,644,061 shares (or prefunded warrants) at $0.609 each.","Concurrent private placement: warrants for 11,288,122 shares at $0.609, exercisable upon stockholder approval, 5-year term.","Exercise price of 3,113,213 existing outstanding warrants reduced to $0.609 and expiration extended to 2028, subject to shareholder approval.","Net proceeds for therapeutic DNA production development and general corporate purposes; closing expected Feb 2, 2024.","Placement agent Maxim Group LLC; lock-up on insiders for 60 days post-closing."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-008937","json":"https://secwatch.observer/filing/0001104659-24-008937.json","markdown":"https://secwatch.observer/filing/0001104659-24-008937.md","text":"https://secwatch.observer/filing/0001104659-24-008937.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/744452/000110465924008937/0001104659-24-008937-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/744452/000110465924008937/tm244700d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T12:13:48.668951+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7a55f8bd854b55888af63d833cf92d807700589f","claim":"BNB PLUS CORP. entered into Purchase Agreements with certain institutional investors (effective 2024-01-31).","evidence_excerpt":"Also on January 31, 2024, in connection with the Offering, the Company entered into securities purchase agreements (the “Purchase Agreements”) with certain institutional investors (each, a “Purchaser” and, collectively, the “Purchasers”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/744452/000110465924008937/0001104659-24-008937-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional investors"},{"label":"Effective","value":"2024-01-31"}],"fact_type":"material_agreement"},{"claim_id":"cf401fbb772bbe8072243c96bed820708aeab3f0","claim":"BNB PLUS CORP. entered into Placement Agreement with Maxim Group LLC (effective 2024-01-31).","evidence_excerpt":"On January 31, 2024, Applied DNA Sciences, Inc. (“Company”) entered into a placement agency agreement (the “Placement Agreement”) with Maxim Group LLC (the “Placement Agent”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/744452/000110465924008937/0001104659-24-008937-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Maxim Group LLC"},{"label":"Effective","value":"2024-01-31"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}